VIDEO from Medialink and International HIFU
(See video from International HIFU at: http://media.medialink.com/WebNR.aspx?story=36220)
Existing treatments however, can be limited and affect quality of life due to significant side effects, including loss of muscle mass, depression, decreased mental acuity and impotence. Now a High Intensity Focused Ultrasound (HIFU) procedure, available in 33 countries outside the US including
By focusing sound waves in a targeted area, HIFU can rapidly increase the temperature in the focal zone, causing tissue destruction. This procedure is radiation-free and doesn’t preclude any other treatment options.
For more information regarding the risks and benefits associated with HIFU, go to www.InternationalHIFU.com.
NOTE: Sonablate(R) 500 is not approved for use in the U.S. It remains investigational in the U.S. and is being studied as a prostate cancer treatment in clinical trials in the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate(R) 500 for the treatment of prostate cancer. USHIFU is a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound technologies. International HIFU is the entity through which USHIFU conducts its international business operations and makes the HIFU technologies available to US patients at centers outside
Registered journalists can access video, audio, text, graphics and photos for free and unrestricted use at http://www.mediaseed.tv.
SOURCE Medialink; International HIFU